Xuri Li, November 17
SciLifeLab The Svedberg seminar series
Monday, November 17
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guangzhou, P. R. China
Dr. Xuri Li received her PhD from Karolinska Institutet in Stockholm and did her postdoc work in Leuven University in Belgium. She then moved to the National Institutes of Health, National Eye Institute in the US as a Principal Investigator in 2005 and established and led her own lab there. In 2012, Dr. Li moved to China as the Scientific Director of the State Key Laboratory of Ophthalmology at the Zhongshan Ophthalmic Center, Sun Yat-Sen University in Guangzhou. The State Key Laboratory of Ophthalmology is the only one of its kind in China and founded by the central government. Dr. Li’s major scientific interests include angiogenesis, neovascular diseases and growth factor biology and her team has made many important findings in these areas during the past decade or so.
PDGF-C/D and VEGF-B in normal physiology and pathologies
PDGF-C and PDGF-D were discovered in 2000 and 2001 after many years of intensive studies on the classic PDGFs, PDGF-A and PDGF-B. Studies from the past decade have demonstrated their important roles during development, normal physiology and different pathologies such as cancer, vascular, neural and kidney disorders, suggesting their therapeutic potential in the treatment of cancer and neurovascular diseases. VEGF-B was discovered as a VEGF-A homolog in 1996. Despite of its name, the outcomes of the subsequent studies on the vascular effect VEGF-B have been quite controversial. We have shown that VEGF-B is minimally angiogenic under most conditions. Instead, it is critically required for cell survival under degenerative conditions, indicating its distinct functional profile as compared with the other VEGF family members.
Host: Jia Mi